Harm reduction is a public health framework that acknowledges drug use occurs in society and focuses on minimizing associated risks rather than promoting abstinence-only approaches. This reference is maintained with input from organizations including DanceSafe and TripSit. Content is educational and intended for research and public health awareness.
🚨 MEDICAL EMERGENCY: If you or someone nearby is unresponsive, not breathing normally, or showing signs of overdose — call emergency services (911 / 999 / 112) immediately. This information is educational. It does not replace emergency medical care.
Harm reduction is a set of practical strategies and ideas aimed at reducing negative consequences associated with drug use. As a movement for social justice, harm reduction embraces the dignity of people who use drugs. As a public health strategy, it has demonstrated success in reducing overdose deaths, disease transmission, and drug-related health complications — without requiring abstinence as a precondition for support.
Key principles underlying the harm reduction framework include: meeting people where they are without judgment, providing practical information about risk reduction, supporting autonomy and informed decision-making, and reducing barriers to healthcare and support services. Organizations such as DanceSafe (dancesafe.org), TripSit (tripsit.me), Harm Reduction International (hri.global), and The Loop (UK) are global leaders in harm reduction practice and research.
This guide does not endorse or encourage the use of any controlled substance. It provides factual safety information for people who may encounter these substances, in line with established harm reduction principles used by public health authorities worldwide.
These six principles apply to all substances. No matter what substance is involved, following these principles substantially reduces the risk of serious harm.
Use reagent test kits (Marquis, Mecke, Simon's, Folin) and fentanyl test strips to identify substances and detect dangerous adulterants before use. Unregulated drug supplies frequently contain unexpected substances, including fentanyl analogues in non-opioid drugs. Testing is the single most effective intervention for preventing unexpected overdose.
Begin with the smallest possible dose when using an unfamiliar substance, a new batch, or after a period of abstinence (which significantly lowers tolerance). Tolerance to opioids drops rapidly after even 2–3 days without use. Edible cannabis can take 60–120 minutes to take effect. Allow sufficient time before re-dosing. Patience is among the most effective harm reduction strategies.
Using alone means there is no one to intervene in an overdose or medical emergency. If you must use alone, call the Never Use Alone hotline (1-800-484-3731 in the US) — an operator stays on the line and can call emergency services to your location if you become unresponsive. Using with a trusted person present dramatically increases survival odds in an emergency.
Opioid overdose: slow/stopped breathing, blue lips or fingertips, unresponsive, pinpoint pupils. Stimulant overdose: rapid heart rate, chest pain, seizure, severe overheating. Depressant overdose (benzos, GHB, alcohol): unresponsive but may appear to be sleeping, shallow breathing. Recognition speed determines survival outcome — learn the signs for every substance you or people around you may encounter.
Drug combinations multiply risk unpredictably. The most dangerous combinations involve CNS depressants: opioids + benzodiazepines, opioids + alcohol, GHB + alcohol. These combinations cause synergistic respiratory depression that can be fatal at doses that would be survivable individually. Always check combinations using the TripSit combo checker before mixing any substances.
Good Samaritan laws exist in many US states and other jurisdictions, providing legal protection to people who call emergency services for a drug overdose. Fear of legal consequences has contributed to preventable overdose deaths. In a medical emergency, call for help immediately. Most jurisdictions prioritize saving lives over prosecution. SAMHSA's helpline (1-800-662-4357) provides confidential support 24/7 without judgment.
The following information covers the primary risk factors, overdose signs, and harm reduction strategies for commonly encountered substances. This information is educational and drawn from established harm reduction literature.
Primary risks: Respiratory depression (breathing slows or stops), overdose, physical dependence, withdrawal.
Overdose signs: Very slow, shallow, or stopped breathing; blue or purple lips and fingertips (cyanosis); unresponsive to stimulation; gurgling or "death rattle" sounds; pinpoint (very small) pupils.
Fentanyl risk: Illicitly manufactured fentanyl (IMF) and its analogues (carfentanil, nitazenes) are present in the drug supply far beyond heroin. Fentanyl is 50–100 times more potent than morphine. A dose invisible to the naked eye is lethal. Use fentanyl test strips on every batch, every time. A positive fentanyl test means the risk of overdose is significantly elevated and extreme caution (far smaller test dose) is required.
Naloxone: Carry naloxone (Narcan). Nasal naloxone: insert nozzle into nostril, press plunger. If no response in 2–3 minutes, administer second dose. Call emergency services. Naloxone wears off in 30–90 minutes — the person may re-overdose after naloxone wears off if the opioid is longer-acting.
Critical combination warning: Never mix with benzodiazepines, alcohol, or any other CNS depressant. This combination is responsible for the majority of opioid overdose deaths.
Primary risks: Hyperthermia (overheating), hyponatremia (low sodium from excessive water intake), cardiovascular stress, serotonin syndrome, adulteration with methamphetamine or cathinones ("bath salts").
Hyperthermia: MDMA impairs the body's temperature regulation. In hot environments or during prolonged dancing, body temperature can rise to dangerous levels (>40°C / 104°F). Take regular breaks, move to cooler areas, and monitor temperature. Hyperthermia is a leading cause of MDMA-related hospitalization and death.
Hydration balance: Drink water moderately — approximately 500ml (one pint) per hour if dancing, less if resting. Drinking too much water is also dangerous: hyponatremia (diluted sodium) caused by excessive water intake is responsible for several MDMA-related deaths, particularly in female users. Do not drink large volumes of water quickly.
Testing: Use the Marquis reagent — authentic MDMA turns purple-black. A different color indicates a different substance. Simon's reagent distinguishes MDMA from MDA (turns blue for MDMA, no color for MDA). Cathinones ("bath salts") do not react correctly to Marquis. Fentanyl test strips should also be used as adulterant screening.
Serotonin syndrome: Never combine MDMA with other serotonergic drugs: MAOIs (including some antidepressants like phenelzine), SSRIs (antidepressants like fluoxetine, sertraline), lithium, tramadol, or other substances that affect serotonin. This combination can cause serotonin syndrome — a potentially fatal condition involving agitation, high temperature, rapid heart rate, and muscle rigidity.
Primary risks: Cardiovascular effects (elevated heart rate, blood pressure, increased stroke and heart attack risk), vasoconstriction, nasal tissue damage, dependence, adulterant exposure (levamisole, phenacetin, fentanyl).
Cardiovascular risk: Cocaine significantly increases heart rate and blood pressure and causes coronary artery spasm. Individuals with pre-existing heart conditions face substantially elevated risk of heart attack even with a single use. Cardiovascular deaths can occur in young, apparently healthy individuals with no prior symptoms. Avoid use with other stimulants or tobacco, which compound cardiovascular stress.
Speedball danger: The combination of cocaine with heroin or other opioids ("speedball") carries extremely high overdose risk. The stimulant effect of cocaine masks the respiratory depression of opioids, leading users to underestimate opioid dose. When the cocaine wears off, severe respiratory depression can set in suddenly. This combination is responsible for numerous high-profile overdose deaths.
Adulterants: Levamisole (a veterinary dewormer present in an estimated 80%+ of cocaine supplies) suppresses white blood cell production with chronic exposure. Phenacetin is a carcinogen removed from medicine due to kidney toxicity. Test with reagent kits; however, full adulteration screening for cocaine requires FTIR or mass spectrometry — available from some harm reduction services.
Primary risks: Cardiovascular effects (heart attack, stroke), severe hyperthermia, stimulant psychosis, dependence, neurotoxicity with heavy use.
Cardiovascular risk: Methamphetamine causes significant increases in heart rate and blood pressure and can trigger cardiac arrhythmias, heart attack, and stroke even in young users. Pre-existing heart conditions represent a serious contraindication. Avoid combining with other stimulants (cocaine, MDMA, caffeine at high doses).
Hyperthermia: Like MDMA, methamphetamine impairs temperature regulation. Overheating is a primary cause of methamphetamine-related emergency room visits. Stay in cool environments, avoid heavy physical activity, and monitor body temperature during use.
Stimulant psychosis: Sleep deprivation dramatically accelerates the onset of stimulant psychosis — paranoia, hallucinations, and agitated behavior that can appear after extended use periods, particularly with sleep deprivation. The most effective prevention is adequate sleep. If psychotic symptoms appear, discontinue use, move to a calm environment, and seek medical support.
Harm reduction strategies: Eat before and during use (appetite suppression leads to malnutrition with frequent use). Drink water regularly (dehydration accelerates cardiovascular and psychological risk). Prioritize sleep — the damage from sleep deprivation compounds rapidly over a multi-day run. Establish use limits and rest periods before beginning any session.
Primary risks: Cannabis has low acute toxicity — no recorded fatal overdose from cannabis alone. Primary risks involve psychological effects (anxiety, panic, psychosis in predisposed individuals), impaired coordination, and for heavy users: dependence and cognitive effects.
Edible dosing: Edible cannabis is among the most commonly misused substances. Effects take 45–120 minutes to onset, and peak can occur 2–4 hours after ingestion. This delay leads many users to re-dose before the first dose takes effect, resulting in an intensely uncomfortable experience. Start with 5–10mg THC for edibles if tolerance is unknown. Wait at least 2 hours before considering additional dose.
CBD:THC ratio for anxiety: Higher CBD content can mitigate some THC-induced anxiety. For anxiety-prone users, high-CBD / low-THC products are preferable. Isolated CBD does not cause psychoactive effects and is not associated with anxiety or psychosis risk.
Psychosis risk: Heavy, long-term use of high-potency (high-THC) cannabis is associated with increased risk of cannabis-induced psychosis, particularly in people with a personal or family history of psychotic disorders. This risk is substantially higher with high-potency extracts (concentrates, dabs) compared to flower.
Drug interactions: Cannabis (particularly CBD) inhibits the CYP450 liver enzyme system, affecting the metabolism of many medications including warfarin (blood thinners), anticonvulsants, and some HIV medications. Consult a pharmacist or physician if taking medications that are CYP450-metabolized.
Primary risks: Classic psychedelics have low physiological toxicity — they are not physically addictive and do not cause organ toxicity at typical doses. Primary risks are psychological: anxiety, panic, psychosis in predisposed individuals, persistent perceptual disturbances (HPPD).
Set and setting: The most important harm reduction principle for psychedelics. "Set" refers to mindset — starting a psychedelic experience in a state of significant anxiety, depression, or emotional instability increases the risk of a difficult experience. "Setting" refers to environment — a safe, comfortable, private environment with trusted people is strongly recommended. Avoid public settings, crowded venues, and unfamiliar environments.
Trip sitting: A sober, trusted person present during a psychedelic experience can provide significant support during difficult moments. The trip sitter does not need to take any substance — their role is to provide calm reassurance, ensure physical safety, and seek medical help if needed. For first-time users, a trip sitter is strongly recommended.
Emergency termination: In the event of a severe, unmanageable psychological crisis ("bad trip"), benzodiazepines (diazepam, lorazepam) can rapidly reduce the intensity of the psychedelic experience. This is used in clinical settings for psychedelic-assisted therapy as a "rescue" medication. Antipsychotics are generally avoided as they can cause agitated reactions in some cases.
Adulteration risk: Substances sold as LSD are sometimes other psychedelics (25I-NBOMe, DOx compounds) that carry real toxicity risk. Use an Ehrlich reagent — LSD turns purple; NBOMe compounds do not react. Fentanyl test strips are also recommended for LSD blotters. Psilocybin mushrooms can be tested with Mecke reagent.
Primary risks: Physical dependence (develops faster than most drugs), dangerous withdrawal, respiratory depression (especially in combination with opioids or alcohol), blackout at high doses, cognitive impairment.
Dependence risk: Benzodiazepine physical dependence can develop within days to weeks of daily use. This is much faster than commonly understood. Stopping abruptly after physical dependence has developed can cause withdrawal seizures, which can be fatal — making benzodiazepine withdrawal one of the few withdrawal syndromes that is directly life-threatening (alongside alcohol withdrawal). Never stop benzodiazepines abruptly after daily use of more than a few weeks.
Withdrawal risk: Benzodiazepine withdrawal is more medically dangerous than opioid withdrawal. Opioid withdrawal is extremely uncomfortable but rarely fatal in otherwise healthy people. Benzodiazepine and alcohol withdrawal can cause fatal seizures. A supervised tapering schedule — gradually reducing dose over weeks or months — is the standard of care for managing benzodiazepine cessation. Always seek medical supervision.
Combination dangers: Benzodiazepines combined with opioids, alcohol, or other CNS depressants cause synergistic respiratory depression. This combination is implicated in a significant majority of all prescription drug overdose deaths. Even a single episode of combining benzodiazepines with opioids at doses that seem safe individually can result in fatal respiratory depression during sleep.
Novel benzodiazepines: The research chemical market includes numerous novel benzodiazepines (flualprazolam, clonazolam, flunitrazolam) with extremely high potency and long half-lives. Dosing precision is critical — tiny differences in dose can mean the difference between therapeutic and overdose. These substances carry all the same dependence and withdrawal risks as pharmaceutical benzodiazepines.
Primary risks: Dissociation, emergence delirium, bladder damage (with chronic use), psychological dependence, the "k-hole" (profound dissociative state).
Bladder damage: Ketamine cystitis (bladder damage) is a significant harm associated with chronic heavy ketamine use. Symptoms include severe abdominal pain, frequent urination, blood in urine, and — in severe cases — permanent bladder damage requiring surgical reconstruction. The mechanism is not fully understood but frequency and volume of use are the primary risk factors. Bladder damage is largely irreversible once established. This is among the most underappreciated long-term harms of heavy ketamine use.
The k-hole: At higher doses, ketamine produces a profound dissociative state ("k-hole") in which the user may be unable to move, communicate, or comprehend their environment. While physiologically ketamine is relatively safe at typical doses, the k-hole creates significant accident risk — falling, choking on vomit, temperature regulation failure, aspiration of vomit. Always use in a safe horizontal position with someone monitoring. Place in the recovery position if unresponsive.
K-cramps: Acute abdominal cramping associated with ketamine use (colloquially called "k-cramps") is a widely reported phenomenon, particularly with heavy use. Its mechanism is not well understood. Severe k-cramps in the context of regular use are a warning sign of developing ketamine-related organ damage and may indicate need to reduce or cease use.
Primary risks: Extremely narrow dosing window (recreational dose and overdose dose are close together), synergistic and potentially fatal interaction with alcohol, unconsciousness resembling sleep (making bystander identification of overdose difficult).
Narrow dosing window: The difference between a dose that produces the desired effect and a dose that produces unconsciousness is small — often less than 0.5ml for GBL. GBL is a prodrug that converts to GHB in the body and is typically more potent milligram-for-milligram. Measuring GHB/GBL precisely requires a syringe or graduated dropper — "eyeballing" is unsafe. Concentration varies between batches; always start with the smallest possible test dose with any new source.
Alcohol interaction: Combining GHB or GBL with alcohol is potentially fatal. Both are GABA-ergic CNS depressants with synergistic effects — their combination causes respiratory depression far more severe than either substance alone. Even moderate alcohol consumption combined with GHB significantly increases overdose risk. If you are at an event where GHB is present, do not drink alcohol at the same time.
Overdose presentation: GHB overdose typically presents as deep unconsciousness that appears indistinguishable from ordinary sleep. The person may be breathing and have a pulse, but cannot be roused. This is frequently misidentified as someone who is "just sleeping it off," which can be fatal if breathing subsequently deteriorates. Anyone who cannot be woken from apparent sleep in a context where GHB may have been used should be placed in the recovery position and monitored continuously, with emergency services called if there is any doubt.
Recovery position: If someone is unconscious from GHB overdose, place them on their side (recovery position) to prevent aspiration of vomit, which is a primary cause of GHB-related deaths. Monitor breathing continuously. Call emergency services. There is no pharmacological reversal agent for GHB.
These steps apply to a suspected opioid overdose. For other overdose types, step 1 (call emergency services) is always correct. Steps 4–5 are specific to opioid overdose.
Do not wait to see if the person "comes around." In an opioid overdose, breathing may stop within minutes. Delaying the call is the most common factor in preventable overdose deaths. In many jurisdictions, Good Samaritan laws protect callers from drug-related charges when calling for an overdose. Say clearly: "Someone is unresponsive and not breathing normally. I think it may be a drug overdose. I need an ambulance at [address]."
Rub your knuckles firmly on the person's sternum (breastbone) or call their name loudly. If no response, check for normal breathing — look for chest rise, listen for breath sounds. If breathing is very slow (fewer than 1 breath per 5 seconds), very shallow, or absent, proceed immediately. If the person responds and appears to be breathing adequately, stay with them and monitor.
If the person is unconscious but breathing, place them on their side (recovery position): bend the top knee to 90 degrees, place the top arm under their head for support. This prevents choking on vomit, which is a leading cause of death in unconscious individuals. Do not leave them on their back if unconscious. Continue monitoring breathing until emergency services arrive.
For nasal naloxone (Narcan): tilt the head back slightly. Insert the nozzle into one nostril and press the plunger firmly to deliver the full dose. If no response (no change in breathing or responsiveness) after 2–3 minutes, administer a second dose into the other nostril. For injectable naloxone: inject into the outer muscle of the thigh (can be administered through clothing). Naloxone is safe to administer even if the substance involved is not definitely opioids.
Naloxone wears off in 30–90 minutes. If the person received a long-acting opioid (methadone, extended-release oxycodone, or a fentanyl analogue), they may re-overdose after the naloxone wears off. Do not leave them alone even if they appear to have recovered. Emergency services need to evaluate and potentially administer additional naloxone or supportive care.
In the United States, 48 states have enacted Good Samaritan laws providing some degree of legal protection for people who call for help during a drug overdose. Protections vary by state — some cover only the person who calls, others cover the person experiencing the overdose as well. Fear of legal consequences must not prevent calling for emergency help. A life is always worth the risk of a conversation with police. For legal information by state, visit the National Harm Reduction Coalition website.
Reagent testing provides an important layer of protection against dangerous adulterants and misrepresented substances. No test provides 100% certainty about substance identity or purity, but testing is substantially better than not testing.
MDMA: purple-black. Amphetamine: orange-brown. DXM: gray-black. Opiates: orange-brown to red-brown. No reliable reaction for cocaine, benzodiazepines, or most psychedelics. The most widely used and versatile single reagent for stimulant identification.
MDMA: green-black. Opiates: blue-green. DXM: yellow-green. Useful as a complement to Marquis for confirming MDMA and identifying opiates. Psilocybin mushrooms: teal-green (can be used directly on mushroom tissue).
Distinguishes MDMA from MDA: MDMA turns blue; MDA produces no color change. Also differentiates secondary amines (MDMA) from primary amines (MDA, methamphetamine). Use after a positive Marquis result to confirm MDMA specifically.
Detects indole-containing compounds including LSD (turns purple-violet), psilocybin (purple), and DMT (purple). Does not react to NBOMe compounds, DOx compounds, or many LSD analogues. A purple reaction confirms the presence of an indole alkaloid, though it cannot distinguish between them.
Primarily used for identifying MDMA precursors and some substituted phenethylamines. Less commonly used in personal testing kits but available from harm reduction suppliers. Useful in combination with other reagents for comprehensive profiling.
Dissolve a small sample in water; dip strip for 15 seconds; read after 2–5 minutes. One line = fentanyl detected (high risk). Two lines = fentanyl not detected. Detects most common fentanyl analogues. Does not detect all novel opioids (nitazenes). Available from DanceSafe and local harm reduction services.
If you or someone you know is struggling with substance use, the following resources provide confidential support without judgment. All resources below are free and available 24/7 unless noted.
Phone: 1-800-662-4357
Free, confidential, 24/7 treatment referral and information service for individuals and families facing mental health and substance use disorders. Available in English and Spanish. No insurance required.
Text HOME to 741741
Free, 24/7 crisis counseling via text message. Available for any crisis including substance use emergencies, mental health crises, and suicidal ideation. US, UK, Ireland, and Canada.
Website: wearetheloop.org
UK-based drug checking service and harm reduction organization operating at festivals and events. Provides real-time drug testing and harm reduction advice directly to people at events.
Website: hri.global
International NGO working to reduce the harms of drug use and drug policies. Publishes research, advocates for evidence-based policy, and supports harm reduction programs globally.
Phone: 1-800-484-3731
Free hotline for people using drugs alone. An operator stays on the line during use and can call emergency services to your location if you become unresponsive. Available in the United States.
Website: tripsit.me
Online harm reduction community offering real-time chat support, drug information database, combination safety checker, and factsheets for most substances. Non-judgmental peer support available.
Harm reduction is a public health approach that accepts that some people will use drugs regardless of legal status or social discouragement, and focuses on reducing the risks associated with that use rather than demanding abstinence as a precondition for support. It does not endorse or encourage drug use. Major public health organizations including the World Health Organization (WHO) recognize harm reduction as an evidence-based approach. Examples include needle exchange programs, naloxone distribution, drug checking services, and safer use education like this guide.
The most dangerous drug combinations involve multiple central nervous system depressants together: opioids combined with benzodiazepines, opioids combined with alcohol, GHB combined with alcohol, or any combination of CNS depressants. These combinations cause synergistic respiratory depression — each drug alone depresses breathing, and combined the effect is multiplicative, not additive. The TripSit drug combination checker at tripsit.me/combo is a reliable real-time resource for checking any specific combination's risk level.
Dissolve a small amount of the substance in water (approximately 1/4 teaspoon of water per small residue amount). Dip the fentanyl test strip in the water for 15 seconds, then lay it flat and read after 2–5 minutes. One line indicates fentanyl detected (positive test — high risk). Two lines indicates fentanyl not detected (negative test). A positive result means the substance contains fentanyl or a fentanyl analogue and requires extreme caution. Fentanyl test strips are available from DanceSafe (dancesafe.org) and many local harm reduction programs.
Naloxone (brand name Narcan) is an opioid antagonist that rapidly reverses opioid overdose by blocking opioid receptors. It is available as a nasal spray and injectable formulation. For nasal naloxone: tilt the person's head back, insert the nozzle into one nostril, and press the plunger firmly. If no response after 2–3 minutes, administer a second dose in the other nostril. Call emergency services regardless of response. Naloxone wears off in 30–90 minutes — the person may re-overdose. Naloxone has no effect on non-opioid overdoses and is completely safe to administer if uncertain whether opioids are involved.
GHB overdose presents as deep unconsciousness (the person looks asleep but cannot be roused) and is frequently and fatally misidentified as ordinary sleep. Call emergency services immediately. Place the person in the recovery position (on their side) to prevent choking if they vomit. Monitor breathing continuously — if breathing stops or becomes very slow, begin rescue breaths. Do not leave the person alone under any circumstances. There is no reversal agent for GHB (naloxone does not work on GHB); the only treatment is supportive care and monitoring by emergency services.